Zhansaya Nurgaliyeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhansaya Nurgaliyeva has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Nailya Kozhekenova
Faculty of Medicine and Healthcare, Al-Farabi Kazakh National University, 71 Al-Farabi Avenue, Almaty, 050038, Kazakhstan.
4 shared publications - Natalya Glushkova
Department of Epidemiology, Biostatistics and Evidence-Based Medicine, al-Farabi Kazakh National University, Almaty, Kazakhstan
4 shared publications - Ainash Oshibayeva
Faculty of Medicine, Khoja Akhmet Yassawi International Kazakh-Turkish University, Turkestan 160000, Kazakhstan
3 shared publications - Malika Idayat
Department of Medicine and public health, Al-Farabi Kazakh National University, Almaty, Kazakhstan
3 shared publications - Anastassiya Miller
School of Sciences and Humanities, Nazarbayev University, Astana, Kazakhstan
2 shared publications - Elena von der Lippe
Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, Germany
2 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (22) , 3923
Regional Differences in the Burden of MDR-TB and XDR-TB in Kazakhstan Between 2013 and 2022
Background/Objectives: Tuberculosis (TB) remains one of the leading infectious causes of death worldwide, while multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB continue to pose major global health challenges. Kazakhstan is among the 30 high MDR-TB burden countries prioritized by the World Health Organization (WHO). This study aimed to assess national and regional trends in the burden of MDR-TB and XDR-TB in Kazakhstan between 2013 and 2022. Methods: We conducted a retrospective population-based study using anonymized case-level records of the National Tuberculosis Register of Kazakhstan for 2013–2022; duplicate registrations due to transfers were removed. Crude and age-standardized prevalence and mortality rates were calculated at the national and regional levels. Disability-adjusted life years (DALYs) were estimated as the sum of years of life lost (YLL) and years lived with disability (YLD), following the Global Burden of Disease methodology, using WHO-based treatment durations and HIV-specific disability weights. The burden was additionally assessed by sex and age group, and associations between regional burden and socio-economic and health-system indicators were assessed using Spearman correlation and linear mixed models. Results: Between 2013 and 2022, crude MDR-TB prevalence decreased from 40.80 to 22.35 per 100,000 population (−45.2%) and XDR-TB prevalence from 2.12 to 0.05 per 100,000 (−97.8%). TB mortality among MDR-TB patients decreased by 71.5%, and no XDR-TB deaths were recorded in 2022. The age-standardized DALY rate of drug-resistant TB decreased from 97.0 to 27.8 per 100,000 (−71.3%). DALYs were 2.3–2.6 times higher among men than among women, with the greatest burden in working-age groups. In 2022, the highest burden was observed in West Kazakhstan, Kyzylorda and North Kazakhstan. DR-TB prevalence was higher in regions with more recipients of targeted social assistance, and per capita income was not associated with the burden; higher physician density was associated with lower DALY rates in the main analysis, but not consistently in sensitivity analyses. Conclusions: Kazakhstan experienced substantial reductions in the burden of MDR-TB and XDR-TB during 2013–2022. However, persistent sex and regional differences indicate that these improvements were not uniform across the population. Continued surveillance and targeted interventions in higher-burden population groups and regions remain important for further reducing the burden of drug-resistant TB.
- 16 November 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (22) , 3923
Open AccessRegional Differences in the Burden of MDR-TB and XDR-TB in Kazakhstan Between 2013 and 2022
Background/Objectives: Tuberculosis (TB) remains one of the leading infectious causes of death worldwide, while multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB continue to pose major global health challenges. Kazakhstan is among the 30 high MDR-TB burden countries prioritized by the World Health Organization (WHO). This study aimed to assess national and regional trends in the burden of MDR-TB and XDR-TB in Kazakhstan between 2013 and 2022. Methods: We conducted a retrospective population-based study using anonymized case-level records of the National Tuberculosis Register of Kazakhstan for 2013–2022; duplicate registrations due to transfers were removed. Crude and age-standardized prevalence and mortality rates were calculated at the national and regional levels. Disability-adjusted life years (DALYs) were estimated as the sum of years of life lost (YLL) and years lived with disability (YLD), following the Global Burden of Disease methodology, using WHO-based treatment durations and HIV-specific disability weights. The burden was additionally assessed by sex and age group, and associations between regional burden and socio-economic and health-system indicators were assessed using Spearman correlation and linear mixed models. Results: Between 2013 and 2022, crude MDR-TB prevalence decreased from 40.80 to 22.35 per 100,000 population (−45.2%) and XDR-TB prevalence from 2.12 to 0.05 per 100,000 (−97.8%). TB mortality among MDR-TB patients decreased by 71.5%, and no XDR-TB deaths were recorded in 2022. The age-standardized DALY rate of drug-resistant TB decreased from 97.0 to 27.8 per 100,000 (−71.3%). DALYs were 2.3–2.6 times higher among men than among women, with the greatest burden in working-age groups. In 2022, the highest burden was observed in West Kazakhstan, Kyzylorda and North Kazakhstan. DR-TB prevalence was higher in regions with more recipients of targeted social assistance, and per capita income was not associated with the burden; higher physician density was associated with lower DALY rates in the main analysis, but not consistently in sensitivity analyses. Conclusions: Kazakhstan experienced substantial reductions in the burden of MDR-TB and XDR-TB during 2013–2022. However, persistent sex and regional differences indicate that these improvements were not uniform across the population. Continued surveillance and targeted interventions in higher-burden population groups and regions remain important for further reducing the burden of drug-resistant TB.
- Open Access
- 22 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
An approach to assess the impact of measures mitigating burden associated with COVID-19 in Central Asia (Kazakhstan, Kyrgyzstan, Mongolia)
The COVID-19 pandemic prompted extraordinary response measures in Central Asia ( Kazakhstan, Kyrgyzstan, and Mongolia), but mortality outcomes varied. This retrospective population-based ecological study assessed age-standardized COVID-19 mortality rates (ASMRs per 100,000) from January 2020 to December 2021. Monthly COVID-19 deaths and population data by age and sex were obtained from official statistical and health sources. ASMRs were calculated using direct age standardization; monthly trends were examined by country, sex, and age group using joinpoint regression and interpreted in relation to governmental mitigation measures and circulating SARS-CoV-2 variants. Rates were higher in men than in women: in Kazakhstan, 24.8 vs. 12.8 in 2020 and 87.3 vs. 67.6 in 2021, in Kyrgyzstan, 46.6 vs. 25.2 and 40.8 vs. 29.7, respectively; and in Mongolia, 91.5 vs. 73.1 in 2021, with no deaths reported in 2020. In 2021, the gap between men and women narrowed as female ASMR increased fivefold. COVID-19 mortality was observed among infants in Kazakhstan and children ages 0–4 in Mongolia (2021). Rates rose sharply from age 60, especially among men and showed distinct country-specific timing: an early peak in Kyrgyzstan, delayed acceleration in Kazakhstan, and a late rise in Mongolia. These results underscore the need for timely, coordinated, age- and sex-sensitive response measures and targeted protection of vulnerable groups.
- 22 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessAn approach to assess the impact of measures mitigating burden associated with COVID-19 in Central Asia (Kazakhstan, Kyrgyzstan, Mongolia)
The COVID-19 pandemic prompted extraordinary response measures in Central Asia ( Kazakhstan, Kyrgyzstan, and Mongolia), but mortality outcomes varied. This retrospective population-based ecological study assessed age-standardized COVID-19 mortality rates (ASMRs per 100,000) from January 2020 to December 2021. Monthly COVID-19 deaths and population data by age and sex were obtained from official statistical and health sources. ASMRs were calculated using direct age standardization; monthly trends were examined by country, sex, and age group using joinpoint regression and interpreted in relation to governmental mitigation measures and circulating SARS-CoV-2 variants. Rates were higher in men than in women: in Kazakhstan, 24.8 vs. 12.8 in 2020 and 87.3 vs. 67.6 in 2021, in Kyrgyzstan, 46.6 vs. 25.2 and 40.8 vs. 29.7, respectively; and in Mongolia, 91.5 vs. 73.1 in 2021, with no deaths reported in 2020. In 2021, the gap between men and women narrowed as female ASMR increased fivefold. COVID-19 mortality was observed among infants in Kazakhstan and children ages 0–4 in Mongolia (2021). Rates rose sharply from age 60, especially among men and showed distinct country-specific timing: an early peak in Kyrgyzstan, delayed acceleration in Kazakhstan, and a late rise in Mongolia. These results underscore the need for timely, coordinated, age- and sex-sensitive response measures and targeted protection of vulnerable groups.
- Open Access
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srpski medicinski casopis Lekarske komore
- Vol. 7 (1) , 23-41
Navigating COVID-19 in pregnancy: Care pathways and system challenges in Kazakhstan: A qualitative study
Introduction: International studies conducted during the COVID-19 pandemic have shown that pregnant women often experienced significant barriers to timely and appropriate care. However, much of the existing evidence is derived from quantitative surveillance or from settings with well-established digital infrastructure and standardized clinical pathways, which may not reflect the realities of many middle-income health systems. This study aims to qualitatively explore the experiences of pregnant women and healthcare professionals regarding COVID-19 care pathways, including symptom recognition, outpatient management, and hospitalization, in Almaty, Kazakhstan. Methods: The present study applied a qualitative, descriptive, phenomenological design to explore how pregnant COVID-19 patients and healthcare professionals experienced the organization of care during the pandemic. The study included 24 participants from local primary health care and hospital settings in Almaty, Kazakhstan. Fifteen healthcare professionals and nine pregnant or postpartum women voluntarily and anonymously provided informed consent to in-depth semi-structured interviews, either face-to-face or via secure video conferencing, between May and August 2023. Results: Healthcare professionals reported that COVID-19 substantially altered maternal health care due to increased workload, fear of infection, and a shift toward remote care. Uncertainty regarding pregnancy-specific clinical guidelines and standard operating procedures (SOPs) contributed to reliance on general protocols and informal practices, while delayed hospitalization was linked to symptom denial, fear of admission, self-treatment, and system constraints. Pregnant and postpartum women commonly misinterpreted COVID-19 symptoms as pregnancy-related or mild illness, leading to self-medication and delayed help-seeking. Follow-up was largely unstructured and based on communication via phone or messages. The experience of care varied, ranging from timely clinical support to inconsistent monitoring and preference for home-based management. Conclusion: The study offers detailed insights into a fragile and fragmented COVID-19 care pathway for pregnant women in primary and hospital care settings in Almaty. Several priorities for strengthening care organization for pregnant women with COVID-19 and for future public health emergencies include improving continuity of care, reducing delays in escalation, and enhancing the safety of maternal health services during infectious disease outbreaks.
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srpski medicinski casopis Lekarske komore
- Vol. 7 (1) , 23-41
Open AccessNavigating COVID-19 in pregnancy: Care pathways and system challenges in Kazakhstan: A qualitative study
Introduction: International studies conducted during the COVID-19 pandemic have shown that pregnant women often experienced significant barriers to timely and appropriate care. However, much of the existing evidence is derived from quantitative surveillance or from settings with well-established digital infrastructure and standardized clinical pathways, which may not reflect the realities of many middle-income health systems. This study aims to qualitatively explore the experiences of pregnant women and healthcare professionals regarding COVID-19 care pathways, including symptom recognition, outpatient management, and hospitalization, in Almaty, Kazakhstan. Methods: The present study applied a qualitative, descriptive, phenomenological design to explore how pregnant COVID-19 patients and healthcare professionals experienced the organization of care during the pandemic. The study included 24 participants from local primary health care and hospital settings in Almaty, Kazakhstan. Fifteen healthcare professionals and nine pregnant or postpartum women voluntarily and anonymously provided informed consent to in-depth semi-structured interviews, either face-to-face or via secure video conferencing, between May and August 2023. Results: Healthcare professionals reported that COVID-19 substantially altered maternal health care due to increased workload, fear of infection, and a shift toward remote care. Uncertainty regarding pregnancy-specific clinical guidelines and standard operating procedures (SOPs) contributed to reliance on general protocols and informal practices, while delayed hospitalization was linked to symptom denial, fear of admission, self-treatment, and system constraints. Pregnant and postpartum women commonly misinterpreted COVID-19 symptoms as pregnancy-related or mild illness, leading to self-medication and delayed help-seeking. Follow-up was largely unstructured and based on communication via phone or messages. The experience of care varied, ranging from timely clinical support to inconsistent monitoring and preference for home-based management. Conclusion: The study offers detailed insights into a fragile and fragmented COVID-19 care pathway for pregnant women in primary and hospital care settings in Almaty. Several priorities for strengthening care organization for pregnant women with COVID-19 and for future public health emergencies include improving continuity of care, reducing delays in escalation, and enhancing the safety of maternal health services during infectious disease outbreaks.
- Open Access
- 12 September 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (18) , 2314
Prevalence of Tuberculosis in Central Asia and Southern Caucasus: A Systematic Literature Review
Background: In 2023, tuberculosis (TB) caused 1.25 million deaths globally, remaining a leading infectious killer. Central Asia and Southern Caucasus face high TB burdens, particularly Mongolia. This review synthesizes TB prevalence data and diagnostic capabilities in these regions to support public health strategies. Methods: This systematic review aimed to synthesize current data on TB prevalence in Central Asia, Southern Caucasus, and Mongolia to support public health strategies and research priorities. A comprehensive search of PubMed and Google Scholar was conducted for English-language articles published up to 2023. Studies were assessed using a modified Newcastle–Ottawa Scale. Nine studies met the inclusion criteria, covering Kazakhstan, Kyrgyzstan, Uzbekistan, Tajikistan, Turkmenistan, Mongolia, Georgia, Armenia, and Azerbaijan. Results: TB incidence ranged from 67 per 100,000 in Kazakhstan to 190 per 100,000 in Kyrgyzstan, with the highest prevalence of 68.5% in Mongolia. TB affected men more frequently (65.3%), and the key risk factors included HIV (30.5%), comorbidities, and undernutrition. Diagnostic performance varied significantly (microscopy sensitivity, 45–65%; GeneXpert MTB/RIF, 89–96% sensitivity and 98% specificity for rifampicin resistance). Diagnostic turnaround times ranged from hours (molecular) to weeks (conventional). Only 58% of TB facilities had GeneXpert technology, with urban–rural disparities in diagnostic access. Drug-resistant TB imposed a significant economic burden, with treatment costs ranging from USD 106 to USD 3125. Conclusions: Strengthening surveillance, improving data collection, and conducting longitudinal studies are essential for designing effective TB control strategies in these regions. Significant diagnostic gaps persist across these regions, especially with regard to drug-resistant strains. Point-of-care molecular diagnostics, improved algorithms, and expanded laboratory training show promise. Future research should focus on rapid biomarker-based diagnostics, field-deployable technologies for settings with limited resources, and AI integration to enhance diagnostic accuracy and efficiency.
- 12 September 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (18) , 2314
Open AccessPrevalence of Tuberculosis in Central Asia and Southern Caucasus: A Systematic Literature Review
Background: In 2023, tuberculosis (TB) caused 1.25 million deaths globally, remaining a leading infectious killer. Central Asia and Southern Caucasus face high TB burdens, particularly Mongolia. This review synthesizes TB prevalence data and diagnostic capabilities in these regions to support public health strategies. Methods: This systematic review aimed to synthesize current data on TB prevalence in Central Asia, Southern Caucasus, and Mongolia to support public health strategies and research priorities. A comprehensive search of PubMed and Google Scholar was conducted for English-language articles published up to 2023. Studies were assessed using a modified Newcastle–Ottawa Scale. Nine studies met the inclusion criteria, covering Kazakhstan, Kyrgyzstan, Uzbekistan, Tajikistan, Turkmenistan, Mongolia, Georgia, Armenia, and Azerbaijan. Results: TB incidence ranged from 67 per 100,000 in Kazakhstan to 190 per 100,000 in Kyrgyzstan, with the highest prevalence of 68.5% in Mongolia. TB affected men more frequently (65.3%), and the key risk factors included HIV (30.5%), comorbidities, and undernutrition. Diagnostic performance varied significantly (microscopy sensitivity, 45–65%; GeneXpert MTB/RIF, 89–96% sensitivity and 98% specificity for rifampicin resistance). Diagnostic turnaround times ranged from hours (molecular) to weeks (conventional). Only 58% of TB facilities had GeneXpert technology, with urban–rural disparities in diagnostic access. Drug-resistant TB imposed a significant economic burden, with treatment costs ranging from USD 106 to USD 3125. Conclusions: Strengthening surveillance, improving data collection, and conducting longitudinal studies are essential for designing effective TB control strategies in these regions. Significant diagnostic gaps persist across these regions, especially with regard to drug-resistant strains. Point-of-care molecular diagnostics, improved algorithms, and expanded laboratory training show promise. Future research should focus on rapid biomarker-based diagnostics, field-deployable technologies for settings with limited resources, and AI integration to enhance diagnostic accuracy and efficiency.
- Open Access
- 12 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-14
The burden of COVID-19 in primary care of Almaty, Kazakhstan, 2021–2022
Primary healthcare played a crucial role during the COVID-19 pandemic by preventing, timely diagnosing, and referring severe cases to hospitals, as well as monitoring and counseling patients via telemedicine. We used a cross-sectional approach to analyze the severity outcomes of 174,540 COVID-19 cases treated in primary care in Almaty between 2021 and 2022, by age, sex, disease severity, and comorbidities. Outpatients with COVID-19 were mainly aged 30–39 (20.3%) with a mild course (88.9%). Among adults, females predominated (≥ 60–25.5% vs. 19.2%, < 0.001), and among children (0–17), boys − 21.2% vs. 12.1% (p < 0.001). A higher risk for moderate to severe COVID-19 and adverse outcomes was assessed among older adults, particularly those aged 60 and older compared with younger groups (OR = 9.01, 95% CI: 7.72–10.51). Pregnant women had a low risk of severe disease (OR = 0.5, 95% CI: 0.38–0.65). Patients with concomitant disease were at higher likelihood of severe COVID-19 (p < 0.001, OR = 2.51, 95% CI: 1.9–3.15 for obesity, p < 0.001, OR = 1.43, 95% CI: 1.27–1.6 for diabetes mellitus, OR = 1.16, 95% CI: 1.07–1.26 for arterial hypertension, and p < 0.001, OR = 2.5, 95% CI: 2.13–3.02 for chronic obstructive pulmonary disease). The study emphasizes an often-overlooked impact of COVID-19 on primary care, which is essential for improving outpatient care.
- 12 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-14
Open AccessThe burden of COVID-19 in primary care of Almaty, Kazakhstan, 2021–2022
Primary healthcare played a crucial role during the COVID-19 pandemic by preventing, timely diagnosing, and referring severe cases to hospitals, as well as monitoring and counseling patients via telemedicine. We used a cross-sectional approach to analyze the severity outcomes of 174,540 COVID-19 cases treated in primary care in Almaty between 2021 and 2022, by age, sex, disease severity, and comorbidities. Outpatients with COVID-19 were mainly aged 30–39 (20.3%) with a mild course (88.9%). Among adults, females predominated (≥ 60–25.5% vs. 19.2%, < 0.001), and among children (0–17), boys − 21.2% vs. 12.1% (p < 0.001). A higher risk for moderate to severe COVID-19 and adverse outcomes was assessed among older adults, particularly those aged 60 and older compared with younger groups (OR = 9.01, 95% CI: 7.72–10.51). Pregnant women had a low risk of severe disease (OR = 0.5, 95% CI: 0.38–0.65). Patients with concomitant disease were at higher likelihood of severe COVID-19 (p < 0.001, OR = 2.51, 95% CI: 1.9–3.15 for obesity, p < 0.001, OR = 1.43, 95% CI: 1.27–1.6 for diabetes mellitus, OR = 1.16, 95% CI: 1.07–1.26 for arterial hypertension, and p < 0.001, OR = 2.5, 95% CI: 2.13–3.02 for chronic obstructive pulmonary disease). The study emphasizes an often-overlooked impact of COVID-19 on primary care, which is essential for improving outpatient care.